CTOs on the Move


 
The founders of NXT-ID were an integral part of the senior management teams at Technest Holdings, Inc., and its subsidiary Genex Technologies. Genex Technologies was founded in 1995 to develop and commercialize the unique Rainbow® method of capturing 3D data. Since its founding Genex has developed into one of the market leaders in advanced imaging, including 3D and 360-degree technologies. Genex has developed innovative technologies and products for all aspects of imaging, including capture, processing, display, and enhancement. Genex’s products range from 3D cameras to surveillance algorithms to integrated facial recognition systems. Genex and Technest have won awards from the Department ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.nxt-id.com
  • 4 Research Dr Ste 402
    Shelton, CT USA 06484
  • Phone: 203.242.3076

Executives

Name Title Contact Details

Similar Companies

Meso Scale Discovery

Meso Scale Discovery is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immusoft

Immusoft Corporation (immusoft.com) is a pre-clinical gene therapy company based in Seattle, Wash. Its mission is to treat diseases using its breakthrough technology platform called Immune System Programming.

Timken Radiology

Timken Radiology is a Winter Park, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cannalysis Labs

Cannalysis was founded in 2015, in Costa Mesa CA. Initially, Cannalysis exclusively served Southern California with a limited amount of analyses available. As the operational and testing requirements expanded, Cannalysis moved its headquarters to a 12,000 sqft state-of-the-art facility in Santa Ana, CA.

Predicine

Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology and infectious diseases. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology and infectious diseases, including COVID-19. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, Berlin and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.